The novel antiretroviral combination Bixlenvo (bictegravir-lenacapavir) maintains high viral suppression in HIV patients, even when preexisting resistance-associated mutations are present.
Findings from the phase 3 ARTISTRY-2 trial, presented at HIV Glasgow 2026, demonstrate that the regimen performs as effectively as current standard-of-care treatments over 48 weeks of therapy.
- Consistent Efficacy: The BIC/LEN regimen successfully suppressed viral loads in patients regardless of whether they arrived at the study with preexisting drug resistance.
- Standard Comparison: The study compared Bixlenvo against the established BIC/FTC/TAF (Biktarvy) regimen, confirming non-inferiority in clinical outcomes.
The ARTISTRY-2 trial evaluated 574 participants living with HIV to determine if switching to a bictegravir-lenacapavir (BIC/LEN) single-tablet regimen could maintain viral control. The trial specifically assessed whether baseline resistance-associated mutations—genetic changes in the virus that can render standard drugs less effective—would compromise the new combination. Statistical analysis indicated that these mutations had no significant impact on the efficacy of the regimen (P>0.05).
The trial design necessitated a rigorous comparison against the standard-of-care, BIC/FTC/TAF (Biktarvy). By the 48-week mark, the data showed that phenotypic susceptibility to the study medications was maintained across the cohort. The rarity of treatment-emergent mutations—occurring in only one participant—suggests that this dual-drug approach provides a stable therapeutic option for populations with complex antiretroviral histories.
Bixlenvo functions through a synergistic mechanism of action, combining two distinct classes of antiretroviral agents. Bictegravir is an integrase strand transfer inhibitor (INSTI), which prevents the HIV genome from integrating into the host cell’s DNA. Lenacapavir, a capsid inhibitor, interferes with multiple stages of the viral lifecycle, including capsid-mediated nuclear uptake and the assembly and release of new viral particles.
This dual-action approach helps patients who have developed resistance to earlier generations of antiretrovirals. By attacking the virus at two different, critical points in its replication cycle, the regimen lowers the probability that a single mutation will allow the virus to escape treatment. This is the primary driver behind the high rates of viral suppression observed in the ARTISTRY-2 trial.
The trial was sponsored and funded by Gilead Sciences, the manufacturer of both Bixlenvo and Biktarvy.
- HIV Glasgow 2026: Abstract 048, “Efficacy and Safety of Bictegravir/Lenacapavir in Treatment-Experienced Patients.”
- Infectious Disease Special Edition, Bixlenvo Maintains Viral Suppression in ARTISTRY-2 Trial.
